This article is reproduced from the 97th issue of “Ganoderma” magazine in 2023, published with author’s permission. All rights to this article belong to the author.
A significant difference can be observed in the brain between a healthy individual (левый) and an Alzheimer’s disease patient (верно).
(Image source: Wikimedia Commons)
Alzheimer’s disease (AD), commonly known as senile dementia, is a progressive neurodegenerative disorder characterized by age-related cognitive impairment and memory loss. With the increase in human lifespan and population aging, the prevalence of Alzheimer’s disease is steadily rising, posing a significant burden on families and society. Поэтому, exploring multiple approaches to prevent and treat Alzheimer’s disease has become a topic of great research interest.
In my article titled “Exploring the Research on Ганодерма for Preventing and Treating Alzheimer’s Disease,” published in the 83rd issue of “Ganoderma” magazine in 2019, I introduced the pathogenesis of Alzheimer’s disease and the pharmacological effects of Ганодерма яркая in preventing and treating Alzheimer’s disease. Specifically, Ганодерма яркая extracts, Ганодерма яркая полисахариды, Ганодерма яркая тритерпены, и Ганодерма яркая spore powder were found to improve learning and memory impairments in Alzheimer’s disease rat models. These components also exhibited protective effects against degenerative neuropathological changes in the hippocampal brain tissue of the Alzheimer’s disease rat models, reduced neuroinflammation in brain tissues, increased the activity of superoxide dismutase (ДЕРН) in the hippocampal brain tissue, decreased the levels of malondialdehyde (MDA) as an oxidative product, and demonstrated preventive and therapeutic effects in experimental animal models of Alzheimer’s disease.
The two preliminary clinical studies on Ганодерма яркая for preventing and treating Alzheimer’s disease, introduced in the article, have not definitively confirmed the effectiveness of Ганодерма яркая in Alzheimer’s disease. Однако, combined with numerous promising pharmacological research findings, they provide hope for further clinical studies.
The effect of usingГанодерма яркая spore powder alone to treat Alzheimer’s disease is not obvious.
Reviewing the research paper titled “Spore powder of Ганодерма яркая for the treatment of Alzheimer’s disease: A pilot study” published in the journal “Medicine” [1], the authors randomly divided 42 patients who met the diagnostic criteria for Alzheimer’s disease into an experimental group and a control group, с 21 patients in each group. The experimental group received oral administration of Ганодерма яркая spore powder capsules (SPGL group) at a dosage of 4 капсулы (250 mg each capsule) three times a day while the control group only received placebo capsules. Both groups underwent a 6-week treatment.
At the end of the treatment, compared to the control group, the SPGL group showed a reduction in scores for the Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-cog) and the Neuropsychiatric Inventory (NPI), indicating an improvement in cognitive and behavioral impairments, but the differences were not statistically significant (Стол 1). The World Health Organization Quality of Life-BREF (WHOQOL-BREF) questionnaire showed an increase in life quality scores, indicating an improvement in life quality, but again, the differences were not statistically significant (Стол 2). Both groups experienced mild adverse reactions, with no significant differences.
The authors of the paper believe that the treatment of Alzheimer’s disease with Ганодерма яркая spore powder capsules for 6 weeks did not show significant therapeutic effects, possibly due to the short duration of treatment. Future clinical trials with large sample sizes and longer treatment durations are needed to gain a clearer understanding of the clinical efficacy of Ганодерма яркая spore powder capsules in the treatment of Alzheimer’s disease.
The combined use ofГанодерма яркая spore powder with conventional treatment drugs significantly improves the therapeutic efficacy in treating Alzheimer’s disease.
Недавно, a study evaluated the combined effects of Ганодерма яркая spore powder and the Alzheimer’s disease medication memantine on cognition and quality of life in patients with mild to moderate Alzheimer’s disease [2]. Forty-eight patients diagnosed with Alzheimer’s disease, aged 50 к 86 годы, were randomly divided into a control group and an experimental group, с 24 patients in each group (n=24).
Prior to treatment, there were no statistically significant differences between the two groups in terms of gender, dementia degree, ADAS-cog, NPI, and WHOQOL-BREF scores (P>0.5). The control group received memantine capsules at a dose of 10 mg, twice a day, while the experimental group received the same dose of memantine along with Ганодерма яркая spore powder capsules (SPGL) at a dose of 1000 mg, three times a day. Both groups were treated for 6 недели, and the basic data of the patients were recorded. The cognitive function and quality of life of the patients were assessed using the ADAS-cog, NPI, and WHOQOL-BREF scoring scales.
После лечения, both groups of patients showed a significant reduction in ADAS-cog and NPI scores compared to before treatment. Кроме того, the experimental group had significantly lower ADAS-cog and NPI scores than the control group, with statistically significant differences (П<0.05) (Стол 3, Стол 4). Following treatment, both groups of patients demonstrated a significant increase in scores for physiology, psychology, social relationships, среда, and overall quality of life in the WHOQOL-BREF questionnaire compared to before treatment. Более того, the experimental group had significantly higher WHOQOL-BREF scores than the control group, with statistically significant differences (П<0.05) (Стол 5).
Memantine, known as a novel N-methyl-D-aspartate (NMDA) receptor antagonist, can non-competitively block NMDA receptors, thereby reducing glutamic acid-induced NMDA receptor overexcitation and preventing cell apoptosis. It improves cognitive function, behavioral disorder, activities of daily living, and dementia severity in patients with Alzheimer’s disease. It is used for the treatment of mild, moderate, and severe Alzheimer’s disease. Однако, the use of this medication alone still has limited benefits for patients with Alzheimer’s disease.
The results of this study show that the combined application of Ганодерма яркая spore powder and memantine can enhance patients’ behavioral and cognitive abilities and significantly improve their quality of life.
Choosing the right medication approach is crucial for treating Alzheimer’s disease.
In the above two randomized controlled clinical trials of Ганодерма яркая spore powder for the treatment of Alzheimer’s disease, the selection of cases, diagnosis, source of Ganoderma lucidum spore powder, dosage, курс лечения, и показатели оценки эффективности были одинаковыми, но клиническая эффективность была разной. После статистического анализа, использование Ганодерма яркая Использование только порошка спор для лечения болезни Альцгеймера не показало значительного улучшения AS-cog., NPI, и показатели WHOQOL-BREF по сравнению с плацебо; однако, комбинированное использование Ганодерма яркая порошок спор и мемантин показали значительное улучшение по трем показателям по сравнению с одним мемантином., то есть, комбинированное использование Ганодерма яркая споровый порошок и мемантин могут значительно улучшить поведенческие способности., когнитивные способности и качество жизни пациентов с болезнью Альцгеймера.
В настоящее время, препараты, используемые для лечения болезни Альцгеймера, например, донепезил, ривастигмин, мемантин, и галантамин (Реминил), имеют ограниченный терапевтический эффект и могут лишь облегчить симптомы и отсрочить течение заболевания.. Кроме того, almost no new drugs for the treatment of Alzheimer’s disease have been successfully developed in the past 20 годы. Поэтому, использованиеГанодерма яркая spore powder to enhance the efficacy of drugs for the treatment of Alzheimer’s disease should be given attention.
As for further clinical trials of using Ганодерма яркая spore powder alone, it may be possible to consider increasing the dosage, for example, 2000 mg each time, twice a day, for a course of at least 12 недели. Whether this is feasible, we look forward to research results in this area to tell us the answer.
[Ссылки]
1. Guo-hui Wang, и др.. Spore powder ofГанодерма яркая for the treatment of Alzheimer disease: A pilot study. Medicine（Baltimore）. 2018；97(19): e0636.
2. Wang Lichao, и др.. The effect of memantine combined withГанодерма яркая spore powder on cognition and quality of life in patients with Alzheimer’s disease. Journal of Armed Police Medical College (Medical Edition). 2019, 28(12): 18-21.
Знакомство с профессором Линь Чжибинем
Мистер. Линь Жибин, пионер в Ганодерма исследования в Китае, посвятил почти полвека этой области. Он занимал несколько должностей в Пекинском медицинском университете., включая вице-президента, Заместитель декана факультета фундаментальной медицины, Директор Института фундаментальных медицинских наук, и директор кафедры фармакологии. Сейчас он профессор кафедры фармакологии Школы фундаментальных медицинских наук Пекинского университета.. От 1983 к 1984, он был приглашенным научным сотрудником в Исследовательском центре традиционной медицины ВОЗ при Университете Иллинойса в Чикаго.. От 2000 к 2002, он был приглашенным профессором в Университете Гонконга. С 2006, он был почетным профессором Пермской государственной фармацевтической академии в России..
С 1970, он использовал современные научные методы для изучения фармакологических эффектов и механизмов традиционной китайской медицины. Ганодерма и его активные ингредиенты. Он опубликовал более ста научных статей по Ганодерма.. От 2014 к 2019, он был включен в список высоко цитируемых исследователей Китая журнала Elsevier шесть лет подряд..
Он написал много книг о Ганодерма., включая «Современные исследования Ганодерма»(1ст-4-е издания), «Линчжи от тайны к науке»(1ст-3-е издания), «Ганодерма поддерживает здоровую энергию и рассеивает патогенные факторы., помощь в лечении опухолей», «Дискуссии о Ганодерма», и «Ганодерма и здоровье»..
